Cervical Cancer

New Protocol: Tisotumab Vedotin in Combination with Carboplatin, Pembrolizumab, or Bevacizumab in Recurrent or Metastatic Cervical Cancer

2023-06-07

  • Study

    Phase Ib/II, open-label, multicenter study
    Recurrent or stage IV cervical cancer
    Arm D: Tisotumab vedotin + Carboplatin (first line, n=33); Arm E: Tisotumab + Pembrolizumab (first line, n=33); Arm F: Tisotumab + pembrolizumab (2nd-3rd line, n=35

  • Efficacy

    cORR: 54.5% vs. 40.6% vs. 35.3%
    mDoR: 8.6 vs. NR vs. 14.1 mos
    mPFS: 6.9 vs. 5.3 vs. 5.6 mos

  • Safety

    Grade≥ 3: Anemia (39.4% vs. 12.1% vs. 28.6%), diarrhea (15.2% vs. 1% vs. 5.7%)


    • J Clin Oncol AUG 31; 2023

    Vergote Ignace et al. Tisotumab Vedotin in Combination With Carboplatin, Pembrolizumab, or Bevacizumab in Recurrent or Metastatic Cervical Cancer: Results From the innovaTV 205/GOG-3024/ENGOT-cx8 Study

    http://doi.org/10.1200/JCO.23.00720

    Reviewed by Elvin CHALABİYEV, MD on SEP 10, 2023